Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Kerr

Showing results (341-350 of 1,654) with videos related to

Pageof 166
Sort By:
The New Zealand Medical Journal|September 14, 2023
Recurrent Takotsubo syndrome with variable echocardiographic and electrocardiographic appearancesAleisha Easton, Andrew J Kerr, Jen-Li Looi
Methods in Molecular Biology (Clifton, N.J.)|October 27, 2020
Viruses for Landscape-Scale Therapy: Biological Control of Rabbits in AustraliaPeter J Kerr, Robyn N Hall, Tanja Strive
European Journal of Cancer & Clinical Oncology|August 1, 1985
How much does liver disease affect the pharmacokinetics of adriamycin?S B Kaye, J Cummings, D J Kerr
The New Zealand Medical Journal|July 10, 2025
Low-density lipoprotein cholesterol management after acute coronary syndrome in Aotearoa New Zealand: opportunities for improvement (ANZACS-QI 81)Jack L He, Mildred Lee, Andrew J Kerr
Anti-Cancer Drugs|December 1, 1991
The effect of cisplatin and carboplatin on c-myc promoter in erythroleukemic cellsA Eliopoulos, D J Kerr, D A Spandidos
Clinical Pharmacokinetics|July 31, 1999
Can pharmacokinetic monitoring improve clinical use of fluorouracil?A M Young, S Daryanani, D J Kerr
The New England Journal of Medicine|January 29, 2002
Prone positioning of patients with acute respiratory failureKentigern Thorburn, Steve J Kerr, Paul B Baines
Current Opinion in Molecular Therapeutics|November 19, 2002
Clinical experience with adenovirus in cancer therapyDaniel H Palmer, Vivien Mautner, David J Kerr
British Journal of Cancer|April 1, 1993
Effect of polyunsaturated fatty acids on the drug sensitivity of human tumour cell lines resistant to either cisplatin or doxorubicinJ A Plumb, W Luo, D J Kerr
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Can primary osteosarcoma act as a third space after high-dose methotrexate?D Bissett, S B Kaye, D J Kerr
Pageof 166

Showing results (341-350 of 1,654) with videos related to

Sort By:
Pageof 166
The New Zealand Medical Journal|September 14, 2023
Recurrent Takotsubo syndrome with variable echocardiographic and electrocardiographic appearancesAleisha Easton, Andrew J Kerr, Jen-Li Looi
Methods in Molecular Biology (Clifton, N.J.)|October 27, 2020
Viruses for Landscape-Scale Therapy: Biological Control of Rabbits in AustraliaPeter J Kerr, Robyn N Hall, Tanja Strive
European Journal of Cancer & Clinical Oncology|August 1, 1985
How much does liver disease affect the pharmacokinetics of adriamycin?S B Kaye, J Cummings, D J Kerr
The New Zealand Medical Journal|July 10, 2025
Low-density lipoprotein cholesterol management after acute coronary syndrome in Aotearoa New Zealand: opportunities for improvement (ANZACS-QI 81)Jack L He, Mildred Lee, Andrew J Kerr
Anti-Cancer Drugs|December 1, 1991
The effect of cisplatin and carboplatin on c-myc promoter in erythroleukemic cellsA Eliopoulos, D J Kerr, D A Spandidos
Clinical Pharmacokinetics|July 31, 1999
Can pharmacokinetic monitoring improve clinical use of fluorouracil?A M Young, S Daryanani, D J Kerr
The New England Journal of Medicine|January 29, 2002
Prone positioning of patients with acute respiratory failureKentigern Thorburn, Steve J Kerr, Paul B Baines
Current Opinion in Molecular Therapeutics|November 19, 2002
Clinical experience with adenovirus in cancer therapyDaniel H Palmer, Vivien Mautner, David J Kerr
British Journal of Cancer|April 1, 1993
Effect of polyunsaturated fatty acids on the drug sensitivity of human tumour cell lines resistant to either cisplatin or doxorubicinJ A Plumb, W Luo, D J Kerr
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Can primary osteosarcoma act as a third space after high-dose methotrexate?D Bissett, S B Kaye, D J Kerr
Pageof 166